Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2011	Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare.
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
Pharmaceutical Executive December 1, 2008 Patrick Clinton	Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry.
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system.
CIO September 27, 2013	How IT Can Produce Better Patient Care For Dr. Bob Laskowski, president and CEO of Christiana Care Health System, technology means empowering physicians and patients.
Pharmaceutical Executive July 1, 2009 Patrick Clinton	What to Buy In the long run, pharma wants to sell health, not just drugs.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay	Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole.
Pharmaceutical Executive February 1, 2006 Chandler & Chicco	Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Pharmaceutical Executive January 1, 2012 Elys Roberts & Sarah Phillips	The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all?
Pharmaceutical Executive September 1, 2006 Patrick Clinton	From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Pharmaceutical Executive May 1, 2007 Diane West	Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc.
The Motley Fool June 28, 2010 Luke Timmerman	Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system.
Pharmaceutical Executive October 1, 2008 Patrick Clinton	Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Pharmaceutical Executive June 1, 2006 Cindy D'Aoust	Who's Coming to Meetings? Need to attract the "right" physicians to a promotional meeting? Have to do it on a budget while following new compliance rules? Check out this new survey to see how the rest of pharma lives with a shifting promotional landscape.
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
CRM November 2009 Lauren McKay	Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Pharmaceutical Executive March 1, 2009 Brittany Agro	The New Sales Force The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with, and how it's working.
Pharmaceutical Executive July 1, 2012 Al Topin	Marketing: Why the Conversation Has Changed -- Forever At its core, pharma marketing is about conversations. Dynamic, persuasive conversations between companies and healthcare stakeholders. But one time it was simple; now it's not.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Pharmaceutical Executive March 1, 2006 Sharyn Lee	Invisible Prescribers: What You Do and Don't Know About NPs and PAs How many prescriptions are written each year by nurse practitioners and physician assistants? Pharmaceutical companies not only fail to market to this sector, they neglect to invite nurse practitioners and physician assistants to meetings or to include them in plans for continuing medical education.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.
Managed Care February 2007 MargaretAnn Cross	How Much Trouble Does Health Care Marketing Cause? Whether for drugs, imaging, surgery, or emergency services, direct-to-consumer advertising sparks lively debate.
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Pharmaceutical Executive June 1, 2006 Philip A. George	Alternative Media: Online Med Sites Gain Patient Trust Pharma could benefit from a little less TV.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive October 1, 2008	Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
Pharmaceutical Executive April 1, 2006 Christensen, McLaughlin & Wunker	The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better.
The Motley Fool April 29, 2005 Charly Travers	Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc.
Pharmaceutical Executive December 1, 2005 Patrick Clinton	PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products.
Pharmaceutical Executive January 1, 2006 Patrick Clinton	From the Editor: A Wild 25 This has been an amazing quarter century for the pharmaceuticals industry, and it has brought us to a point at which the next quarter century can only be more of the same
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive April 1, 2006 David Duplay	Marketing to Professionals: A Sample Plan Sure, pharmaceutical e-sampling can save money. But there are plenty of other reasons to use it.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
Registered Rep. September 26, 2011 Stan Luxenberg	Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
Pharmaceutical Executive April 1, 2012	Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more.